<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437918</url>
  </required_header>
  <id_info>
    <org_study_id>PDC-07-01</org_study_id>
    <nct_id>NCT00437918</nct_id>
  </id_info>
  <brief_title>The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients</brief_title>
  <official_title>Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In type 2 diabetic patients, tight blood glucose control often requires both fasting and
      post-prandial glucose control separately. In the diabetic patients already on the insulin
      glargine treatment for the control of fasting blood glucose, additional measures for the
      control of post-prandial glucose level are often required. Nateglinide and acarbose are
      frequently used for this purpose. We hypothesized that the short acting sulfonylurea
      &quot;nateglinide&quot; may be more efficacious in diabetic patients with appreciable endogenous
      insulin secretion, while acarbose may be more efficacious in patients with lower endogenous
      insulin secretion. And we also want to clarify the clinical and biochemical parameters that
      can predict the responsiveness to each agent in this multi-center randomized open cross-over
      clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7 point SMBG (self monitoring of blood glucose)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA-beta for predicting the effectiveness of each agents</measure>
  </secondary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nateglinide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Korean

          -  Type 2 diabetes mellitus

          -  No prior history of diabetic ketoacidosis

          -  HbA1c between 7.5-10.0%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Gestational diabetes mellitus

          -  Secondary diabetes mellitus

          -  Severe hyperglycemia with symptoms

          -  Severe chronic diabetic complications (PDR,s-Cr&gt;1.3mg/dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeonghyun Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology and Metabolism, Maryknoll General Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>March 21, 2008</last_update_submitted>
  <last_update_submitted_qc>March 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jeong Hyun Park, MD PhD / Professor</name_title>
    <organization>Inje University Pusan Paik Hospital / Paik Diabetes Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Nateglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

